LLY
Eli Lilly and Company
NYSE
Healthcare
$910.91
+26.39
(+2.98%)
Updated: 3/31/2026, 4:00:01 PM
Open
$893.49
High
$923.98
Low
$887.20
Prev Close
$886.63
Volume
1.06M
Price History
Why Is LLY ▲ Up Today?
+2.98%
Full AI analysis generates after market close. Showing live price data.
Mar 31
▲
+3.0%
LLY Up Nearly 3% on Sleep Medicine Expansion
Mar 30
▲
+0.8%
LLY Up Slightly on AI Drug Discovery Deal
Mar 27
▼
-2.3%
Eli Lilly (LLY) Down 2.29% Amidst Mixed News and Sector Weakness
Mar 26
▼
-1.9%
LLY Declines Amidst Sector Gains
Mar 25
▲
+1.5%
Eli Lilly (LLY) Gains Amidst GLP-1 Optimism, Outperforms Sector
Mar 24
▼
-0.8%
Eli Lilly (LLY) Declines Amidst Sector Gains
Mar 23
▲
+0.3%
Eli Lilly (LLY) modestly up despite sector downturn
Mar 20
▼
-1.2%
LLY Down Slightly Amidst Sector Weakness
Mar 19
—
-0.1%
Eli Lilly (LLY) Slightly Down Amidst Sector Weakness
Mar 18
▼
-1.3%
LLY Down Amid Analyst Downgrade and Obesity Drug Competition
Mar 17
▼
-6.1%
Eli Lilly (LLY) Drops on Analyst Downgrade, Obesity Drug Concerns
Mar 16
▲
+0.4%
LLY edges higher on positive eczema drug trial data
Mar 13
▲
+0.8%
LLY Up Slightly Despite Sector Weakness; China Investment & GLP-1 Progress Boost Sentiment
Mar 12
▼
-2.2%
Eli Lilly (LLY) Down on Obesity Drug Impurity Concerns
Mar 11
▼
-0.3%
LLY Down Slightly Amidst Mixed Sector Performance
Mar 10
▼
-0.7%
LLY Down Slightly Amidst Sector Volatility
Mar 9
▲
+1.6%
LLY Up Slightly Amidst Sector Weakness and Mixed News
Mar 6
▲
+0.7%
LLY Up Slightly Amid Obesity Drug Developments
Mar 5
▼
-2.2%
Lilly (LLY) Down Amidst GLP-1 Market News
Mar 4
▼
-0.2%
Eli Lilly (LLY) dips slightly despite positive sector trends
Mar 3
▼
-1.0%
LLY Down Slightly Amidst Mixed Sentiment
Mar 2
▼
-3.2%
LLY Declines Amid Market Correction and Valuation Concerns
Feb 27
▲
+2.8%
Eli Lilly (LLY) Climbs on Positive Obesity Drug Market Sentiment
Feb 26
▼
-0.7%
Eli Lilly (LLY) dips slightly despite positive obesity drug market news
Feb 25
▼
-1.2%
LLY dips slightly amid sector gains, Ozempic price war
Feb 24
▼
-1.6%
Lilly (LLY) dips as Novo Nordisk plans GLP-1 price cuts.
Feb 23
▲
+4.9%
Eli Lilly (LLY) Surges Nearly 5% Amid Novo Nordisk Weight Loss Drug Concerns
Feb 20
▼
-1.3%
LLY dips slightly despite positive Crohn's data, Taltz-Zepbound combo results
Feb 19
▲
+0.3%
LLY Up Slightly on Positive Clinical Trial Data
Feb 18
▼
-1.7%
LLY Down Slightly Despite Positive Psoriasis-Obesity Trial Data
Financial Highlights
Income Statement
Revenue
$59.42B
Gross Profit
$49.34B
83.0% margin
Operating Income
$22.50B
37.9% margin
Net Income
$18.41B
31.0% margin
EPS (Diluted)
$20.44
Balance Sheet
Total Assets
$114.94B
Total Liabilities
$91.08B
Stockholders' Equity
$23.85B
Cash Flow
Operating Cash Flow
$16.06B
Investing Activities
-$10.09B
Net Cash Flow
$6.42B
Highly Regarded Analysis for LLY
Get a deep-dive analysis including bull/bear cases, technical outlook, price targets, and key catalysts — powered by Highly Regarded's proprietary analysis engine.
Usually takes 10-20 seconds
Analyzing LLY...
Searching financial data and generating insights
Analysis couldn't be generated
Related Articles
Debt
3 min read
Debt Consolidation Loans: How They Work and When to Use One
By Neal Wagner
Financial Planning
7 min read
How Long Will My Money Last in Retirement?
By Justin Estes
Investing
5 min read
How to Invest $1,000
By Justin Estes
Financial Planning
3 min read
How Will Trump’s 2025 Tariffs Impact Your Portfolio?
By Justin Estes
Key Stats
P/E Ratio
44.6x
EPS (Diluted)
$20.44
Gross Margin
83.0%
Operating Margin
37.9%
Net Margin
31.0%
Revenue (Qtr)
$59.42B
Shares Outstanding
895M
LLY News
No recent news for LLY.